The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
While Lilly has thrown in the tau towel with zagotenemab, Cortexyme still sees reasons to press on with atuzaginstat.
Fears of heightened scrutiny by the FDA will be calmed by a look at historic rates of complete response letters.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.